Abstract Objective To observe the effects of Huaiqihuang granules on the immune function in children with severe Mycoplasma pneumoniae pneumonia. Methods Pediatric inpatients with severe Mycoplasma pneumoniae pneumonia were randomly divided into Huaiqihuang granule treatment group (n=51) and conventional treatment group (n=47). The Huaiqihuang granule treatment group was orally administered Huaiqihuang granules in addition to the conventional treatment, while the conventional treatment group received conventional treatment only. Levels of serum IgA, IgG, and IgM, percentages of CD4+ and CD8+ T lymphocyte subsets, and CD4+/CD8+ ratio were examined in the two groups. The incidence rate of respiratory tract re-infection within three months following treatment was compared between the two groups. Results The levels of serum IgA, IgG, and IgM, the percentage of CD4+ T lymphocytes, and the CD4+/CD8+ ratio were significantly higher in the Huaiqihuang granule treatment group than in the conventional treatment group three months after treatment (P < 0.05). In contrast, the percentage of CD8+ T lymphocytes was signifcantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P < 0.05). In addition, the incidence rate of respiratory tract re-infection within three months following treatment was signifcantly lower in the Huaiqihuang granule treatment group than in the conventional treatment group (P < 0.05). Conclusions Huaiqihuang granules can regulate immune functions and reduce the incidence of short-term respiratory tract re-infection in children with severe Mycoplasma pneumoniae pneumonia.
LIU Jin,YAN Hong,CHEN Xiao-Geng et al. Effects of Huaiqihuang granules on immune function in children with severe Mycoplasma pneumoniae pneumonia[J]. CJCP, 2017, 19(7): 759-762.
LIU Jin,YAN Hong,CHEN Xiao-Geng et al. Effects of Huaiqihuang granules on immune function in children with severe Mycoplasma pneumoniae pneumonia[J]. CJCP, 2017, 19(7): 759-762.
Meyer Sauteur PM, Unger WW, Nadal D, et al. Infection with and carriage of Mycoplasma pneumoniae in children[J]. Front Microbiol, 2016, 7:329.
[2]
Medjo B, Atanaskovic-Markovic M, Radic S, et al. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children:clinical features and laboratory diagnosis[J]. Ital J Pediatr, 2014, 40:104.
Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolideresistant M. pneumonia[J]. Front Microbiol, 2016, 7:693.
[9]
Diaz MH, Benitezk AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States:trends in molecular typing and macrolide resistance from 2006 to 2013[J]. J Clin Microbiol, 2015, 53(1):124-130.
[10]
Zhou Z, Li X, Chen X, et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China[J]. Antimicrob Agents Chemother, 2015, 59(2):1048-1051.
Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory mycoplasma pneumoniae pneumonia in children[J]. PLoS One, 2016, 11(5):e0156465.
